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Abstract Numerous peptide receptors have recently been
reported to be expressed or overexpressed in various human
cancers. For instance, somatostatin receptors are particular-
ly frequently expressed in gastroenteropancreatic neuroen-
docrine tumors (GEP-NET), including both primaries and
metastases. The density is often high, and the distribution is
usually homogenous. While various somatostatin receptor
subtypes can be expressed in these tumors, the sst2 is
clearly predominant. These receptors represent the molec-
ular basis for a number of clinical applications, including
symptomatic therapy with octreotide in hormone-secreting
GEP-NET, in vivo diagnostic with radiolabeled diethylene
triamine pentaacetic acid octreotide (Octreoscan) to evalu-
ate the extend of the disease, and 90Y- or 177Lu-[90Y-
DOTA]-D-Phe1-Tyr3 octreotide radiotherapy. GEP-NETcan,
however, express peptide receptors other than somatostatin
receptor: Insulinomas have more glucagon-like peptide 1
receptors than somatostatin receptors; gastrinomas express
very high levels of secretin receptors. GEP-NET may also
express cholecystokinin 2, bombesin, neuropeptide Y, or
vasoactive intestinal peptide receptors. Often, several of
these peptide receptors are expressed simultaneously in
GEP-NET, providing a molecular basis for in vivo multi-
receptor targeting of those tumors.
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Introduction
In the past decade, there has been increasing evidence for
peptide receptor expression on various human cancers
[15]. This observation has permitted to develop in vivo
peptide receptor targeting of these tumors, for diagnostic
and/or therapeutic purposes [12, 13, 15]. The best evidence
has been provided for somatostatin receptors expressed in
neuroendocrine tumors, which can currently be targeted with
111In diethylene triamine pentaacetic acid octreotide for their
in vivo localization or with 90Yttrium- or 177Lutetium-[90Y-
DOTA]-D-Phe1-Tyr3 (DOTATOC) for targeted radiotherapy
[12]. Somatostatin receptor scintigraphy has been shown to
be the diagnostic tool of first choice for a subgroup of gut
neuroendocrine tumors, as it was superior to all other
conventional imaging methods [6], and radiotherapy with
90Y-DOTATOC appears extremely promising in tumors
expressing somatostatin receptors, with more than 25%
remissions and about 50% disease stabilization [10, 14, 23,
25]. More recently, other peptide receptors have emerged as
being overexpressed in selected tumors [15] and appear to
have a promising in vivo targeting potential. These are
bombesin receptors of the BB2 subtype, better known as
gastrin-releasing peptide (GRP) receptors, which are over-
expressed in prostate and breast cancers [15] and can be
visualized in vivo in these tumors [22, 24]. Furthermore,
cholecystokinin (CCK) 2 receptors expressed in medullary
thyroid carcinomas [15] can be selectively targeted in vivo
[1, 11], and more recently, neurotensin receptors were
visualized in exocrine pancreatic carcinomas [2].
Extensive information on in vitro peptide receptor
expression including incidence, density, and subtype char-
acteristics in tumors is required before a novel peptide
receptor is chosen as target for in vivo clinical investiga-
tions in tumor patients. The aim of the present article is to
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review the in vitro evidence for the expression of several
regulatory peptide receptors in cancer tissues with morpho-
logical methods, including receptor autoradiography and
immunohistochemistry. It will focus on human gastro-
enteropancreatic neuroendocrine tumors (GEP-NET) and
somatostatin receptors but will also expand to other peptide
receptors such as vasoactive intestinal peptide (VIP), CCK,
bombesin, neuropeptide Y (NPY), neurotensin (NT),
corticotropin-releasing factor (CRF), and glucagon-like
peptide (GLP-1) receptors.
Somatostatin receptors in GEP-NET
GEP-NET are generally known as a group of tumors
expressing frequently somatostatin receptors. Table 1
summarizes the main features that are explained in more
detail further in the text. There are several possibilities to
detect somatostatin receptors morphologically in tissue
sections [15]. One possibility is in situ hybridization,
which, however, identifies the messenger ribonucleic acid
and not the protein. Another possibility is autoradiography
that identifies the receptor binding site (protein) that can be
pharmacologically characterized and quantitatively
assessed. It is a highly sensitive and specific method.
Recently, it has been improved to identify the five
somatostatin receptor subtypes by using subtype-selective
analogs [18]. One drawback is, however, that in vitro
autoradiography does not have a very high resolution. A
method analyzing the protein with a higher resolution is
receptor immunohistochemistry, which, while dependent on
a high quality antibody, can precisely identify membrane-
bound receptors in formalin-fixed tissues [16].
It is not sufficient to know whether a tumor is
somatostatin receptor positive or negative; it is also
necessary to assess its density, its distribution, and its
somatostatin receptor subtype profile. GEP-NET can have a
wide variability of somatostatin receptor density among
individuals, ranging from low density, as found in lympho-
mas, to high density, as seen in meningiomas, medullo-
blastomas, or growth hormone adenomas. In the majority of
the cases, GEP-NET belong preferably to the group of
tumors with a high density range of receptors. Both
pancreatic NET (including gastrinomas, glucagomas, vipo-
mas) and gut NET (foregut, midgut, and hind gut tumors)
can express somatostatin receptors in 80–100% of the
cases. Insulinomas have a lower incidence (50–70%). In
general, the somatostatin receptors are expressed homoge-
neously in these tumors, a characteristic that represents an
advantage in view of an optimal in vivo targeting of as much
tumor cells as possible during peptide receptor radiotherapy.
Worth mentioning is also the differentiation-dependent
expression of somatostatin receptors. Well-differentiated
tumors express usually somatostatin receptors, while
undifferentiated GEP-NET may not [17]. Such observations
are relevant in regard to therapeutic options [9]. The
existence of five sst subtypes has made the evaluation of
somatostatin receptors in tumors quite complex. There is
consensus, based on various methodologies, that GEP-NET
can often express more than one sst subtype; moreover, sst2
is usually the most prominent, followed by sst1 and sst5,
while sst3 is less frequent and sst4 almost absent [15, 18].
Because excellent sst2-selective antibodies are now avail-
able, the sst2 receptors can conveniently be assessed by
immunohistochemistry on formalin-fixed tissues [7, 16,
21]; if frozen tissue is available, receptor autoradiography
using subtype-selective analogs is the method of choice to
identify the five sst subtypes.
In clinical practice, in vivo Octreoscan scintigraphy has
become the method of choice to evaluate the somatostatin
receptor status in the great majority of GEP-NET patients.
It is a sensitive, specific, and noninvasive method giving
receptor information for the patient’s whole body. How-
ever, next to in vivo scintigraphy, the in vitro somatostatin
receptor evaluation of tumors remains in specific cases an
important additional current diagnostic option. It may
simply be used as a complementary and confirmatory
method to Octreoscan, providing information on sst
subtypes, tissue localization, and on receptor homogeneity.
It may replace Octreoscan if Octreoscan is not available or
uneasy to interpret. The somatostatin receptor status can be
established in vitro, either immunohistochemically in the
formalin-fixed resected tumor using appropriate antibodies
[7, 16, 21] or, if frozen tumor tissue samples have been
secured, by somatostatin receptor autoradiography [17].
Other peptide receptors in GEP-NET
Although somatostatin receptors have been found to be
extremely useful targets for the diagnosis and therapy for a
majority of GEP-NET, it is worth summarizing the data
available for other regulatory peptide receptors in this type
of tumors, as they may potentially play an equally
important role. Indeed, several peptide receptors are
Table 1 Somatostatin receptor expression in GEP-NET
Main features Characteristics
Receptor incidence 80–100% (Most pancreatic and gut NET)
50–70% (Insulinomas)
Receptor density predominantly high
Receptor distribution predominantly homogeneous
Receptor expression differentiated tumor>undifferentiated tumor
Receptor subtype sst2>>sst1=sst5>sst3>>sst4
Receptor localization usually membrane bound (sst2)
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expressed in selected GEP-NET in much higher incidence
and/or density than somatostatin receptors [18].
GLP-1 receptors
This is the case for GLP-1 receptors in insulinomas, which
are expressed in virtually all cases in extremely high
concentrations. We have identified several examples of
insulinomas with a high density of GLP-1 receptors but no
sst2 receptors [18]. Furthermore, gastrinomas express GLP-
1 receptors with a very high incidence but a lower density
than insulinomas. One third of carcinoids have a low to
moderate GLP-1 receptor density, as well as half of the four
tested glucagonomas [18].
CCK receptors
CCK receptors are also widely expressed in GEP-NET.
Virtually all insulinomas express CCK2 receptors, often in
high amounts, but no CCK1 receptors [18]. More than half
of the ileal carcinomas express CCK2 receptors, and one
third expresses CCK1 receptors [18]. In several cases, both
receptor subtypes are expressed concomitantly. Half of the
gastrinomas express CCK1 but not CCK2 receptors.
VIP receptors
Virtually all ileal carcinomas and insulinomas and a large
proportion gastrinomas and glucagonomas express VPAC1,
while VPAC2 is absent [18].
Bombesin receptors
While bombesin receptors are rarely detected in insulino-
mas, gastrinomas express frequently the GRP receptor
subtypes (BB2), while ileal carcinoids preferentially express
the neuromedin B receptor subtype (BB1) [18].
NPY receptors
NPY receptors have been identified in two thirds of ileal
carcinoids and one fourth of pancreatic carcinoids, in a
relatively low density however (Körner and Reubi,
unpublished data).
Secretin receptors
Secretin receptors are expressed in extremely high amounts
in the great majority of gastrinomas cases [8]. These wild-
type secretin receptors are likely to be responsible for the
positive secretin provocation test in Zollinger–Ellison
syndrome [5]. However, these receptors can be silenced if,
exceptionally, they are expressed concomitantly with a
misspliced variant with exon 3 deletion [4].
CRF receptors
Only one study has investigated CRF receptors in GEP
tumors, where only endocrine pancreatic tumors were
analyzed: 6 of 15 insulinomas express CRF2 receptors,
while glucagomas and gastrinomas rarely express CRF1 or
CRF2 receptors [20].
NT receptors
GEP-NET have not been found to express significant
amounts of NT receptors [19].
Multiple receptors
It is now well documented that a large proportion of
GEP-NET can express concomitantly several peptide
receptors that could be used as targets simultaneously.
Insulinomas often express CCK2, GLP-1, sst2, and VPAC1
receptors simultaneously. Gastrinomas are characterized not
only by a very high incidence and density of sst2 and
secretin receptors but also a high incidence of GLP-1
receptors and a marked expression of GRP receptors [18].
The coexpression of multiple receptors in human GEP-NET
may be biologically relevant [18]. Indeed, many of the
involved peptides, e.g., GRP, CCK, VIP, SS, somatostatin
secretin, are known to have growth stimulatory or inhibi-
tory properties [15]. Many of these peptides will affect
tumor growth, depending on the individual receptor profile
of the tumor. Peptide receptor coexpression may also have
clinical implications. The concomitant application of
multiple radioligands may be extremely attractive to
improve the efficacy of peptide targeting in tumors; it will
selectively increase the accumulation of radioactivity in the
tumors, an advantage not only for diagnostic but especially
for radiotherapeutic purposes. Specifically, GLP-1 and
CCK2 receptors may be highly efficient targets in all
insulinomas, and the use of a mixture of sst2, secretin, GLP-
1, and GRP radioligands could offer optimal targeting of
gastrinomas. As some of the receptors are nonhomoge-
Table 2 Selection of peptide receptors expressed in GEP-NET (see
text for detail)
Somatostatin receptors
GLP-1 receptors
Secretin receptors
Cholecystokinin receptors
VIP receptors
Bombesin receptors
CRF receptors
NPY receptors
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neously expressed by tumors, such as CCK1 and CCK2 in
ileal carcinoids [18], a combination of the corresponding
receptor-selective radiopeptides may further improve the
targeting efficacy during radiotherapy by destroying more
than one receptor-expressing tumor area. Furthermore, a
cocktail of different peptides may possibly reduce the risk
of a loss of efficacy during peptide radiotherapy that may
be due to tumor dedifferentiation with a resulting loss of
some but not all peptide receptors. Finally, an advantage of
using a cocktail of radioligands is the possibility to label
each of them with different isotopes namely, with β-
emitters of different ranges to obtain an optimal radiother-
apy for large and small tumoral lesions [3]. Whenever
possible, before the concomitant use of several radiopeptide
ligands in vivo, it would be worth determining the
individual peptide receptor affinity profile of the tumor
under consideration, by in vitro receptor determination
using the previously described methodology in a surgically
resected biopsy sample.
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